New Opportunities for CROs as Pharma and Biotech Outsourcing Grows
Nancy Cecchettini |
Tuesday, April 30, 2013 at 1:27PM Despite recent evidence indicating that the overall number of clinical trials in pre-clinical and Phase I-IV have declined in volume, industry research shows that this lack of new study startups may be offset by a growing trend by pharmaceutical and biotechnology companies to outsource their studies and study management to clinical research organizations. A recent article in PharmaOutsourcing confirms this theory, observing that despite a downturn in the total number of clinical trials in all phases, CROs may still witness a large increase in new clients, as large pharma, biotech and device companies look to keep their costs down.
